Literature DB >> 20882301

[Implications of modern anticancer therapies for palliative care concepts].

B Alt-Epping1, F Nauck.   

Abstract

In modern oncology, paradigmatic developments can be witnessed with respect to conceptual strategies and to individualized diagnostics and treatment approaches, but foremost with respect to the amazing number of new anticancer substances available. These developments will certainly influence the care of patients suffering from incurable and advanced cancer, where pain therapy and symptom control, quality of life and other intentions of palliative care are urgent. For cancer pain therapy and palliative care, knowledge about these developments may be helpful not only with respect to interdisciplinary decision making, but also for thoroughly balancing risks, side effects and benefits of oncological interventions that have the potential to stabilize disease progression and thereby reduce symptom intensity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20882301     DOI: 10.1007/s00482-010-0940-0

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  31 in total

1.  Circulating tumor cells in metastatic breast cancer--toward individualized treatment?

Authors:  Stephan Braun; Christian Marth
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

2.  Antiangiogenic metronomic chemotherapy.

Authors:  Roberta Sarmiento; Giampietro Gasparini
Journal:  Onkologie       Date:  2008-03-20

Review 3.  Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice.

Authors:  D Tassinari; F Drudi; L Lazzari-Agli; P Tombesi; S Sartori
Journal:  Ann Oncol       Date:  2009-11-17       Impact factor: 32.976

4.  Analgesic effects of chemotherapy?

Authors:  A Caraceni; F De Conno
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

5.  Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).

Authors:  R Colomer; E Alba; A González-Martin; L Paz-Ares; M Martín; A Llombart; Á Rodríguez Lescure; J Salvador; J Albanell; D Isla; M Lomas; C A Rodríguez; J M Trigo; J R Germà; J Bellmunt; J Tabernero; R Rosell; E Aranda; R Cubedo; J Baselga
Journal:  Ann Oncol       Date:  2010-02       Impact factor: 32.976

6.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

7.  Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Authors:  Eric Winer; Julie Gralow; Lisa Diller; Beth Karlan; Patrick Loehrer; Lori Pierce; George Demetri; Patricia Ganz; Barnett Kramer; Mark Kris; Maurie Markman; Robert Mayer; David Pfister; Derek Raghavan; Scott Ramsey; Gregory Reaman; Howard Sandler; Raymond Sawaya; Lynn Schuchter; John Sweetenham; Linda Vahdat; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2008-12-22       Impact factor: 44.544

8.  A phase II clinical trial of sorafenib in androgen-independent prostate cancer.

Authors:  William L Dahut; Charity Scripture; Edwin Posadas; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Yunkai Yu; Liang Cao; Seth M Steinberg; Jeanny B Aragon-Ching; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

9.  Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy.

Authors:  Nina Helbekkmo; Ulf Aasebø; Stein H Sundstrøm; Christian von Plessen; Paal Fr Brunsvig; Roy M Bremnes
Journal:  Lung Cancer       Date:  2008-04-15       Impact factor: 5.705

10.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

View more
  1 in total

1.  [Pain therapy in oncology: results of a nationwide survey].

Authors:  B Alt-Epping; J Bauer; U Schuler; F Nauck; I Strohscheer
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.